8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Apr 30, 2026·SEC
Material company update
Mar 24, 2026·SEC
TELA Bio, Inc.(TELA)Earnings, Financials & Key Ratios
TELA•NASDAQ
$0.72
Price updated Jul 7, 2026
AboutTELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.Show more
- Revenue$80M+15.8%
- EBITDA-$34M-2.0%
- Net Income-$39M-2.6%
- EPS (Diluted)-0.83+37.6%
- Gross Margin67.69%+0.9%
- EBITDA Margin-42.05%+12.0%
- Operating Margin-42.05%+14.6%
- Net Margin-48.37%+11.4%
- ROE-223.35%-39.7%
TELA Price & Volume
TELA Bio, Inc. (TELA) stock price & volume — 10-year historical chart
Loading chart...
Stagnant Revenue Growth Challenges Capital Structure Sustainability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Decelerating
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and capital exhaustion
Key Thesis Takeaways
- TELA Bio faces a critical inflection point as revenue growth decelerated to 2.9% in 2026Q1, signaling significant friction in its market penetration strategy.
- The company's reliance on a high-cost direct sales force has resulted in persistent operating losses and an erosion of shareholder equity to a negative $5.2M position.
- Investors should monitor the company's ability to manage its $55.9M debt load against a tightening cash runway that contracted to $39.5M in the most recent quarter.
Verdict Logic
the company's persistent net losses and the accumulation of $409.8M in retained earnings suggest a high risk of further shareholder dilution to support ongoing operations.
TELA Growth Metrics
TELA Bio, Inc. (TELA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years34.54%
3 Years24.68%
TTM13.48%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM8.3%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM43.97%
Return on Capital
10 Years-76.72%
5 Years-58.85%
3 Years-58.99%
Last Year-49.94%
TELA Recent Earnings
TELA Bio, Inc. (TELA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.21-50.0%
$0.14
Rev
$19M+2.5%
$19M
Q2 2026
Mar 25, 2026Metric
Actual
Est
EPS
$0.16+11.1%
$0.18
Rev
$21M-0.8%
$21M
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.19-11.8%
$0.17
Rev
$21M-1.7%
$21M
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.22-22.2%
$0.18
Rev
$20M-8.8%
$22M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.21vs $0.14-50.0% | $19Mvs $19M+2.5% |
| Q2 2026 | Mar 25, 2026 | $0.16vs $0.18+11.1% | $21Mvs $21M-0.8% |
| Q4 2025 | Nov 13, 2025 | $0.19vs $0.17-11.8% | $21Mvs $21M-1.7% |
| Q3 2025 | Aug 11, 2025 | $0.22vs $0.18-22.2% | $20Mvs $22M-8.8% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for TELA Bio, Inc. (TELA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.72 | $32.23M | -0.87 | 15.84% | -48.37% | -223.35% | — | |
| $0.42 | $58.84M | 13.98 | 14.21% | 1.5% | 3.68% | — | |
| $32.80 | $1.66B | -136.67 | 14.88% | -0.83% | -0.95% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — | |
| $4.32 | $310.89M | -4.60 | -38.1% | -61.93% | -15.09% | — | |
| $72.14 | $4.3B | 33.87 | 11.66% | 9.03% | 8.95% | — |
Compare TELA vs Peers
TELA Bio, Inc. (TELA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TELA SEC Filings & Documents
TELA Bio, Inc. (TELA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when TELA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TELA Frequently Asked Questions
TELA Bio, Inc. (TELA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is TELA Bio, Inc.'s revenue?
TELA Bio, Inc. (TELA) reported $80.8M in revenue for fiscal year 2025. This represents a 1804% increase from $4.2M in 2017.
How fast is TELA Bio, Inc. growing?
TELA Bio, Inc. (TELA) grew revenue by 15.8% over the past year. This is strong growth.
Is TELA profitable?
TELA Bio, Inc. (TELA) reported a net loss of $39.8M for fiscal year 2025.
Dividend & Returns
What is TELA's return on equity?
TELA Bio, Inc. (TELA) has a return on equity (ROE) of -223.4%. Negative ROE indicates the company is unprofitable.
What is TELA Bio, Inc.'s free cash flow?
TELA Bio, Inc. (TELA) had negative free cash flow of $30.2M in fiscal year 2025, likely due to heavy capital investments.